Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRWD5769 Alone and in Combination With Cemiplimab in Advanced Solid Malignancies
NCT06923761Phase 2Active, not recruiting
- Sponsor
- Grey Wolf Therapeutics
- Start
- May 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of GRWD5769 in solid malignancy (2 arms), sponsored by Grey Wolf Therapeutics. Primary endpoints: Number of treatment emergent and treatment related Adverse Events, Incidence of Dose Limiting Toxicities and 1 more. Started May 2023; status: active, not recruiting.
02
Drugs
GRWD5769
03
Conditions
solid malignancy
Beyond the preview
Go deeper on NCT06923761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923761.